Biosimilar eculizumab and meningococcal meningitis: the importance of strengthening health education

This manuscript addresses the development of meningitis associated with biosimilar Eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), emphasizing the importance of health education provided by healthcare professionals for the early detection of meningitis, as well as the relevance of updating vaccination schedules. There are no published reports in the literature on meningitis caused by biosimilar Eculizumab (Bekemv®), a drug marketed in April 2023. The importance of reporting adverse drug reactions (ADRs) to pharmacovigilance systems is highlighted, which contributes to expanding the safety profile of the drug.